Skip to main content
Erschienen in: Wiener klinische Wochenschrift 23-24/2012

01.12.2012 | review article

European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives

verfasst von: Peter Valent, MD, Michel Arock, Patrizia Bonadonna, Knut Brockow, Sigurd Broesby-Olsen, Luis Escribano, Karoline V. Gleixner, Clive Grattan, Emir Hadzijusufovic, Hans Hägglund, Olivier Hermine, Hans-Peter Horny, Hanneke C. Kluin-Nelemans, Marcus Maurer, Marek Niedoszytko, Boguslaw Nedoszytko, Gunnar Nilsson, Hanneke N. G. Oude-Elberink, Alberto Orfao, Deepti Radia, Andreas Reiter, Frank Siebenhaar, Karl Sotlar, Wolfgang R. Sperr, Massimo Triggiani, Jaap J. VanDoormaal, Judit Várkonyi, Selim Yavuz, Karin Hartmann

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 23-24/2012

Einloggen, um Zugang zu erhalten

Summary

The European Competence Network on Mastocytosis (ECNM) was initiated in 2002 as a multidisciplinary and multinational cooperative approach to increase awareness and to improve diagnosis and therapy of mastocytosis. The network is composed of local centers, physicians, and scientists who have dedicated their work to patients with mastocytosis. A strategic goal of the ECNM is to provide the best available information about the disease to patients and physicians. During the past 10 years, the ECNM has expanded to various countries and contributed successfully to the development of markers, definitions, and standards in the field of mastocytosis. Members of the ECNM organized Annual Meetings in Europe and two Working Conferences on Mastocytosis in Vienna (in 2005 and 2010), and initiated and supported several preclinical and clinical trials. In all these activities, representatives of the ECNM cooperate closely with their US colleagues, with patient-organizations in Europe and in the USA, and with other scientific networks. The ECNM also launched a mastocytosis registry that has been activated in 2012. Using the central database of this registry, cooperative multicenter studies, which should include sufficient numbers of patients and robust evaluations, will be conducted. These studies will increase our knowledge about optimal management and therapy of patients with mastocytosis in the future.
Literatur
1.
Zurück zum Zitat Lennert K, Parwaresch MR. Mast cells and mast cell neoplasia: a review. Histopathology. 1979;3:349–65.PubMedCrossRef Lennert K, Parwaresch MR. Mast cells and mast cell neoplasia: a review. Histopathology. 1979;3:349–65.PubMedCrossRef
2.
Zurück zum Zitat Metcalfe DD. Classification and diagnosis of mastocytosis: current status. J Invest Dermatol. 1991;96:2S–4S.CrossRef Metcalfe DD. Classification and diagnosis of mastocytosis: current status. J Invest Dermatol. 1991;96:2S–4S.CrossRef
4.
Zurück zum Zitat Valent P. Biology, classification and treatment of human mastocytosis. Wien Klin Wochenschr. 1996;108:385–97.PubMed Valent P. Biology, classification and treatment of human mastocytosis. Wien Klin Wochenschr. 1996;108:385–97.PubMed
5.
Zurück zum Zitat Escribano L, Akin C, Castells M, Orfao A, Metcalfe DD. Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol. 2002;81:677–90.PubMedCrossRef Escribano L, Akin C, Castells M, Orfao A, Metcalfe DD. Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol. 2002;81:677–90.PubMedCrossRef
6.
Zurück zum Zitat Valent P, Akin C, Sperr WR, Horny HP, Arock M, Lechner K, et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol. 2003;122:1–23.CrossRef Valent P, Akin C, Sperr WR, Horny HP, Arock M, Lechner K, et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol. 2003;122:1–23.CrossRef
7.
Zurück zum Zitat Valent P, Sperr WR, Schwartz LB, Horny HP. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. J Allergy Clin Immunol. 2004;114:3–11.PubMedCrossRef Valent P, Sperr WR, Schwartz LB, Horny HP. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. J Allergy Clin Immunol. 2004;114:3–11.PubMedCrossRef
8.
Zurück zum Zitat Horny HP, Sotlar K, Valent P. Mastocytosis: state of the art. Pathobiology. 2007;74:121–32.PubMedCrossRef Horny HP, Sotlar K, Valent P. Mastocytosis: state of the art. Pathobiology. 2007;74:121–32.PubMedCrossRef
10.
Zurück zum Zitat Arock M, Valent P. Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol. 2010;3:497–516.PubMedCrossRef Arock M, Valent P. Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol. 2010;3:497–516.PubMedCrossRef
11.
Zurück zum Zitat Valent P, Horny H-P, Escribano L, Longley JB, Li CY, Schwartz LB, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Report of ‘Year 2000 Working Conference on Mastocytosis’. Leuk Res. 2001;25:603–25. Valent P, Horny H-P, Escribano L, Longley JB, Li CY, Schwartz LB, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Report of ‘Year 2000 Working Conference on Mastocytosis’. Leuk Res. 2001;25:603–25.
12.
Zurück zum Zitat Valent P, Akin C, Sperr WR, Horny HP, Metcalfe DD. Mast cell proliferative disorders: current view on variants recognized by the World Health Organization. Hematol Oncol Clin North Am. 2003;17:1227–41.PubMedCrossRef Valent P, Akin C, Sperr WR, Horny HP, Metcalfe DD. Mast cell proliferative disorders: current view on variants recognized by the World Health Organization. Hematol Oncol Clin North Am. 2003;17:1227–41.PubMedCrossRef
13.
Zurück zum Zitat Valent P, Horny H-P, Li CY, Longley JB, Metcalfe DD, Parwaresch RM, Bennett JM. Mastocytosis. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization (WHO) classification of tumours of haematopoietic and lymphoid tissues. IARC: Lyon; 2001. pp. 291–302. Valent P, Horny H-P, Li CY, Longley JB, Metcalfe DD, Parwaresch RM, Bennett JM. Mastocytosis. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization (WHO) classification of tumours of haematopoietic and lymphoid tissues. IARC: Lyon; 2001. pp. 291–302.
14.
Zurück zum Zitat Horny HP, Akin C, Metcalfe DD, Bain BJ, Akin C, Escribano L, et al. Mastocytosis (mast cell disease). In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. World Health Organization (WHO) classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC: Lyon; 2008. pp. 54–63. Horny HP, Akin C, Metcalfe DD, Bain BJ, Akin C, Escribano L, et al. Mastocytosis (mast cell disease). In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. World Health Organization (WHO) classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC: Lyon; 2008. pp. 54–63.
15.
Zurück zum Zitat Sperr WR, Horny HP, Valent P. Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis. Int Arch Allergy Immunol. 2002;127:140–2.PubMedCrossRef Sperr WR, Horny HP, Valent P. Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis. Int Arch Allergy Immunol. 2002;127:140–2.PubMedCrossRef
16.
Zurück zum Zitat Horny HP, Sotlar K, Sperr WR, Valent P. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol. 2004;57:604–8.PubMedCrossRef Horny HP, Sotlar K, Sperr WR, Valent P. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol. 2004;57:604–8.PubMedCrossRef
17.
Zurück zum Zitat Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113:5727–36.PubMedCrossRef Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113:5727–36.PubMedCrossRef
18.
Zurück zum Zitat Pardanani A, Lim KH, Lasho TL, Finke CM, McClure RF, Li CY, et al. WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. Blood. 2010;115:150–1.PubMedCrossRef Pardanani A, Lim KH, Lasho TL, Finke CM, McClure RF, Li CY, et al. WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. Blood. 2010;115:150–1.PubMedCrossRef
19.
Zurück zum Zitat Sperr WR, Valent P. Diagnosis, progression patterns and prognostication in mastocytosis. Expert Rev Hematol. 2012;5:261–74.PubMedCrossRef Sperr WR, Valent P. Diagnosis, progression patterns and prognostication in mastocytosis. Expert Rev Hematol. 2012;5:261–74.PubMedCrossRef
20.
Zurück zum Zitat Castells M, Austen KF. Mastocytosis: mediator-related signs and symptoms. Int Arch Allergy Immunol. 2002;127:147–52.PubMedCrossRef Castells M, Austen KF. Mastocytosis: mediator-related signs and symptoms. Int Arch Allergy Immunol. 2002;127:147–52.PubMedCrossRef
21.
Zurück zum Zitat Escribano L, Akin C, Castells M, Orfao A, Metcalfe DD. Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol. 2002;81:677–90.PubMedCrossRef Escribano L, Akin C, Castells M, Orfao A, Metcalfe DD. Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol. 2002;81:677–90.PubMedCrossRef
22.
Zurück zum Zitat Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy. 2008;63:226–32.PubMedCrossRef Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy. 2008;63:226–32.PubMedCrossRef
23.
Zurück zum Zitat Bonadonna P, Perbellini O, Passalacqua G, Caruso B, Colarossi S, Dal Fior D, et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol. 2009;123:680–6.PubMedCrossRef Bonadonna P, Perbellini O, Passalacqua G, Caruso B, Colarossi S, Dal Fior D, et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol. 2009;123:680–6.PubMedCrossRef
24.
Zurück zum Zitat Valent P, Akin C, Escribano L, Födinger M, Hartmann K, Brockow K, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37:435–53.PubMedCrossRef Valent P, Akin C, Escribano L, Födinger M, Hartmann K, Brockow K, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37:435–53.PubMedCrossRef
25.
Zurück zum Zitat Sonneck K, Florian S, Müllauer L, Wimazal F, Födinger M, Sperr WR, et al. Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: monoclonal mast cell activation syndrome. Int Arch Allergy Immunol. 2007;142:158–64.PubMedCrossRef Sonneck K, Florian S, Müllauer L, Wimazal F, Födinger M, Sperr WR, et al. Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: monoclonal mast cell activation syndrome. Int Arch Allergy Immunol. 2007;142:158–64.PubMedCrossRef
26.
Zurück zum Zitat Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157:215–25.PubMedCrossRef Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157:215–25.PubMedCrossRef
27.
Zurück zum Zitat Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: proposed diagnostic criteria. J Allergy Clin Immunol. 2010;126:1099–104.e4.PubMedCrossRef Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: proposed diagnostic criteria. J Allergy Clin Immunol. 2010;126:1099–104.e4.PubMedCrossRef
28.
Zurück zum Zitat Hartmann K, Henz BM. Cutaneous mastocytosis—clinical heterogeneity. Int Arch Allergy Immunol. 2002;127:143–6.PubMedCrossRef Hartmann K, Henz BM. Cutaneous mastocytosis—clinical heterogeneity. Int Arch Allergy Immunol. 2002;127:143–6.PubMedCrossRef
29.
Zurück zum Zitat Sokol H, Georgin-Lavialle S, Grandpeix-Guyodo C, Canioni D, Barete S, Dubreuil P, et al. Gastrointestinal involvement and manifestations in systemic mastocytosis. Inflamm Bowel Dis. 2010;16:1247–53.PubMed Sokol H, Georgin-Lavialle S, Grandpeix-Guyodo C, Canioni D, Barete S, Dubreuil P, et al. Gastrointestinal involvement and manifestations in systemic mastocytosis. Inflamm Bowel Dis. 2010;16:1247–53.PubMed
30.
Zurück zum Zitat Delsignore JL, Dvoretsky PM, Hicks DG, O’Keefe RJ, Rosier RN. Mastocytosis presenting as a skeletal disorder. Iowa Orthop J. 1996;16:126–34.PubMed Delsignore JL, Dvoretsky PM, Hicks DG, O’Keefe RJ, Rosier RN. Mastocytosis presenting as a skeletal disorder. Iowa Orthop J. 1996;16:126–34.PubMed
31.
Zurück zum Zitat Valent P, Akin C, Sperr WR, Escribano L, Arock M, Horny HP, et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res. 2003;27:635–41.PubMedCrossRef Valent P, Akin C, Sperr WR, Escribano L, Arock M, Horny HP, et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res. 2003;27:635–41.PubMedCrossRef
32.
Zurück zum Zitat Ellis JM. Urticaria pigmentosa. A report of a case with autopsy. AMA Arch Pathol. 1949;48:426–9. Ellis JM. Urticaria pigmentosa. A report of a case with autopsy. AMA Arch Pathol. 1949;48:426–9.
33.
Zurück zum Zitat Efrati P, Klajman A, Spitz H. Mast cell leukemia? Malignant mastocytosis with leukemia-like manifestations. Blood. 1957;12:869–82.PubMed Efrati P, Klajman A, Spitz H. Mast cell leukemia? Malignant mastocytosis with leukemia-like manifestations. Blood. 1957;12:869–82.PubMed
34.
Zurück zum Zitat Friedman BI, Will JJ, Freiman DG, Braunstein H. Tissue mast cell leukemia. Blood. 1958;13:70–8.PubMed Friedman BI, Will JJ, Freiman DG, Braunstein H. Tissue mast cell leukemia. Blood. 1958;13:70–8.PubMed
35.
Zurück zum Zitat Schwartz LB, Sakai K, Bradford TR, Ren S, Zweiman B, Worobec AS, Metcalfe DD. The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J Clin Invest. 1995;96:2702–10.PubMedCrossRef Schwartz LB, Sakai K, Bradford TR, Ren S, Zweiman B, Worobec AS, Metcalfe DD. The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J Clin Invest. 1995;96:2702–10.PubMedCrossRef
36.
Zurück zum Zitat Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, Metcalfe DD. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A. 1995;92:10560–4.PubMedCrossRef Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, Metcalfe DD. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A. 1995;92:10560–4.PubMedCrossRef
37.
Zurück zum Zitat Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG, Duffy T, Jacobs P, Tang LH, Modlin I. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet. 1996;12:312–4.PubMedCrossRef Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG, Duffy T, Jacobs P, Tang LH, Modlin I. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet. 1996;12:312–4.PubMedCrossRef
38.
Zurück zum Zitat Escribano L, Orfao A, Díaz-Agustin B, Villarrubia J, Cerveró C, López A, Marcos MA, Bellas C, Fernández-Cañadas S, Cuevas M, Sánchez A, Velasco JL, Navarro JL, Miguel JF. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood. 1998;91:2731–6.PubMed Escribano L, Orfao A, Díaz-Agustin B, Villarrubia J, Cerveró C, López A, Marcos MA, Bellas C, Fernández-Cañadas S, Cuevas M, Sánchez A, Velasco JL, Navarro JL, Miguel JF. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood. 1998;91:2731–6.PubMed
39.
Zurück zum Zitat Horny HP, Sillaber C, Menke D, Kaiserling E, Wehrmann M, Stehberger B, Chott A, Lechner K, Lennert K, Valent P. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol. 1998;22:1132–40.PubMedCrossRef Horny HP, Sillaber C, Menke D, Kaiserling E, Wehrmann M, Stehberger B, Chott A, Lechner K, Lennert K, Valent P. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol. 1998;22:1132–40.PubMedCrossRef
40.
Zurück zum Zitat Sperr WR, Escribano L, Jordan JH, Schernthaner GH, Kundi M, Horny HP, Valent P. Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk Res. 2001;25:529–36.PubMedCrossRef Sperr WR, Escribano L, Jordan JH, Schernthaner GH, Kundi M, Horny HP, Valent P. Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk Res. 2001;25:529–36.PubMedCrossRef
41.
Zurück zum Zitat Fritsche-Polanz R, Jordan JH, Feix A, Sperr WR, Sunder-Plassmann G, Valent P, Födinger M. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol. 2001;113:357–64.PubMedCrossRef Fritsche-Polanz R, Jordan JH, Feix A, Sperr WR, Sunder-Plassmann G, Valent P, Födinger M. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol. 2001;113:357–64.PubMedCrossRef
42.
Zurück zum Zitat Valent P, Escribano L, Parwaresch RM, Schemmel V, Schwartz LB, Sotlar K, Sperr WR, Horny HP. Recent advances in mastocytosis research. Summary of the Vienna Mastocytosis Meeting 1998. Int Arch Allergy Immunol. 1999;120:1–7.PubMedCrossRef Valent P, Escribano L, Parwaresch RM, Schemmel V, Schwartz LB, Sotlar K, Sperr WR, Horny HP. Recent advances in mastocytosis research. Summary of the Vienna Mastocytosis Meeting 1998. Int Arch Allergy Immunol. 1999;120:1–7.PubMedCrossRef
43.
Zurück zum Zitat Valent P, Arock M, Bischoff SC, Bühring HJ, Brockow K, Escribano L, Födinger M, Grabbe J, Hartmann K, Henz BM, Horny HP, Kluin-Nelemans HC, Lima M, Marone G, Orfao A, Parwaresch RM, Sillaber C, Sotlar K, Sperr WR, Triggiani M, Van Doormaal JJ, Wolff K, Zuberbier T. The European Competence Network on Mastocytosis (ECNM). Wien Klin Wochenschr. 2004;116:647–51.PubMedCrossRef Valent P, Arock M, Bischoff SC, Bühring HJ, Brockow K, Escribano L, Födinger M, Grabbe J, Hartmann K, Henz BM, Horny HP, Kluin-Nelemans HC, Lima M, Marone G, Orfao A, Parwaresch RM, Sillaber C, Sotlar K, Sperr WR, Triggiani M, Van Doormaal JJ, Wolff K, Zuberbier T. The European Competence Network on Mastocytosis (ECNM). Wien Klin Wochenschr. 2004;116:647–51.PubMedCrossRef
44.
Zurück zum Zitat The European Competence Network on Mastocytosis—ECNM 2006: homepage on web-link: http://www.ecnm.net. (Access: 2012) The European Competence Network on Mastocytosis—ECNM 2006: homepage on web-link: http://​www.​ecnm.​net.​ (Access: 2012)
45.
Zurück zum Zitat Gotlib J, Berubé C, Growney JD, Chen CC, George TI, Williams C, Kajiguchi T, Ruan J, Lilleberg SL, Durocher JA, Lichy JH, Wang Y, Cohen PS, Arber DA, Heinrich MC, Neckers L, Galli SJ, Gilliland DG, Coutré SE. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood. 2005;106:2865–70.PubMedCrossRef Gotlib J, Berubé C, Growney JD, Chen CC, George TI, Williams C, Kajiguchi T, Ruan J, Lilleberg SL, Durocher JA, Lichy JH, Wang Y, Cohen PS, Arber DA, Heinrich MC, Neckers L, Galli SJ, Gilliland DG, Coutré SE. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood. 2005;106:2865–70.PubMedCrossRef
46.
Zurück zum Zitat Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, Böhm A, Gruze A, Samorapoompichit P, Manley PW, Fabbro D, Pickl WF, Sillaber C, Valent P. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood. 2006;107:752–9.PubMedCrossRef Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, Böhm A, Gruze A, Samorapoompichit P, Manley PW, Fabbro D, Pickl WF, Sillaber C, Valent P. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood. 2006;107:752–9.PubMedCrossRef
47.
Zurück zum Zitat Gleixner KV, Mayerhofer M, Sonneck K, Gruze A, Samorapoompichit P, Baumgartner C, Lee FY, Aichberger KJ, Manley PW, Fabbro D, Pickl WF, Sillaber C, Valent P. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica. 2007;92:1451–9.PubMedCrossRef Gleixner KV, Mayerhofer M, Sonneck K, Gruze A, Samorapoompichit P, Baumgartner C, Lee FY, Aichberger KJ, Manley PW, Fabbro D, Pickl WF, Sillaber C, Valent P. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica. 2007;92:1451–9.PubMedCrossRef
48.
Zurück zum Zitat Krauth MT, Mirkina I, Herrmann H, Baumgartner C, Kneidinger M, Valent P. Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells. Clin Exp Allergy. 2009;39:1711–20.PubMedCrossRef Krauth MT, Mirkina I, Herrmann H, Baumgartner C, Kneidinger M, Valent P. Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells. Clin Exp Allergy. 2009;39:1711–20.PubMedCrossRef
Metadaten
Titel
European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives
verfasst von
Peter Valent, MD
Michel Arock
Patrizia Bonadonna
Knut Brockow
Sigurd Broesby-Olsen
Luis Escribano
Karoline V. Gleixner
Clive Grattan
Emir Hadzijusufovic
Hans Hägglund
Olivier Hermine
Hans-Peter Horny
Hanneke C. Kluin-Nelemans
Marcus Maurer
Marek Niedoszytko
Boguslaw Nedoszytko
Gunnar Nilsson
Hanneke N. G. Oude-Elberink
Alberto Orfao
Deepti Radia
Andreas Reiter
Frank Siebenhaar
Karl Sotlar
Wolfgang R. Sperr
Massimo Triggiani
Jaap J. VanDoormaal
Judit Várkonyi
Selim Yavuz
Karin Hartmann
Publikationsdatum
01.12.2012
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 23-24/2012
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-012-0293-z

Weitere Artikel der Ausgabe 23-24/2012

Wiener klinische Wochenschrift 23-24/2012 Zur Ausgabe

mitteilungen der gesellschaft

Vorstand und Ausschuss ab 1. Jänner 2013

mitteilungen der gesellschaft der ärzte in wien

175 Jahre Gesellschaft der Ärzte in Wien